Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GPC Biotech and Pharmion co-develop satraplatin;ends

Executive Summary

GPC Biotech (cancer therapeutics) has licensed to Pharmion (hematology and oncology) exclusive rights to commercialize the Phase III cancer candidate satraplatin for hormone refractory prostate cancer (HRPC) in Europe, Turkey, the Middle East, Australia, and New Zealand.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register